Lupin secures Health Canada approval for Enbrel biosimilar – Rymti


Lupin Limited has secured approval from Health Canada for Rymti, the company’s biosimilar to Enbrel (etanercept), an inhibitor of tumour necrosis factor (TNF).

Rymti is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis.

Lupin said that Rymti is available in Canada as an injectable easy-to-use pre-filled pen as well as a pre-filled syringe.

See also  Takeda's TAK-279 meets primary endpoint in Phase 2b trial for psoriatic arthritis

Dr. Cyrus Karkaria — Lupin Biotech President said: “Lupin is committed to enhancing patient access to high-quality, life-enhancing biosimilars.

“The approval for Rymti in Canada is a key milestone in our endeavors to improving access to medicines. It underscores the scientific success of Lupin’s biosimilar programs and our commitment to advancing healthcare through innovation.”

Share This


Wordpress (0)